JP2008545670A - 疾患を処置するためのジアリールウレア類を含む組合せ治療 - Google Patents

疾患を処置するためのジアリールウレア類を含む組合せ治療 Download PDF

Info

Publication number
JP2008545670A
JP2008545670A JP2008512729A JP2008512729A JP2008545670A JP 2008545670 A JP2008545670 A JP 2008545670A JP 2008512729 A JP2008512729 A JP 2008512729A JP 2008512729 A JP2008512729 A JP 2008512729A JP 2008545670 A JP2008545670 A JP 2008545670A
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008512729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545670A5 (cg-RX-API-DMAC7.html
Inventor
ウルバン・ショイリング
インゴ・ベルナルト
クラウス・ガルベ
ビルギット・シテック
フリーデグント・マイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of JP2008545670A publication Critical patent/JP2008545670A/ja
Publication of JP2008545670A5 publication Critical patent/JP2008545670A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008512729A 2005-05-27 2006-05-13 疾患を処置するためのジアリールウレア類を含む組合せ治療 Pending JP2008545670A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011476 2005-05-27
EP05011478 2005-05-27
EP05011475 2005-05-27
PCT/EP2006/004523 WO2006125539A2 (en) 2005-05-27 2006-05-13 Combination therapy comprising diaryl ureas for treating diseases

Publications (2)

Publication Number Publication Date
JP2008545670A true JP2008545670A (ja) 2008-12-18
JP2008545670A5 JP2008545670A5 (cg-RX-API-DMAC7.html) 2009-05-07

Family

ID=37052960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512729A Pending JP2008545670A (ja) 2005-05-27 2006-05-13 疾患を処置するためのジアリールウレア類を含む組合せ治療

Country Status (10)

Country Link
US (1) US20090306020A1 (cg-RX-API-DMAC7.html)
EP (1) EP1888065A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008545670A (cg-RX-API-DMAC7.html)
KR (1) KR20080012902A (cg-RX-API-DMAC7.html)
AU (1) AU2006251428A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610090A2 (cg-RX-API-DMAC7.html)
CA (1) CA2609387A1 (cg-RX-API-DMAC7.html)
IL (1) IL187085A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007014920A (cg-RX-API-DMAC7.html)
WO (1) WO2006125539A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516553A (ja) * 2008-04-09 2011-05-26 ダウ グローバル テクノロジーズ リミティド ライアビリティ カンパニー ジクロロヒドリン類を回収する多段法及び装置
JP2012523429A (ja) * 2009-04-09 2012-10-04 オンコシレオン,インコーポレイテッド 線維症を処置するための方法およびpi−3キナーゼインヒビターの組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
DE602006017188D1 (de) * 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
TW200835507A (en) * 2006-12-05 2008-09-01 Vioquest Pharmaceuticals Inc Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
ES2429107T3 (es) 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
TW201012467A (en) 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
ES2385276B1 (es) * 2010-02-25 2013-07-05 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
BR112016014481B1 (pt) * 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CN114751899B (zh) * 2022-04-24 2024-03-29 贵州医科大学 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753370A (ja) * 1993-07-19 1995-02-28 Eli Lilly & Co ワートマンニンおよびその類縁体によるホスファチジルイノシトール3−キナーゼの阻害
US20030139605A1 (en) * 1999-01-13 2003-07-24 Bernd Riedl Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors
WO2003086279A2 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
JP5334414B2 (ja) * 2004-09-06 2013-11-06 バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピラゾロピリミジン

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753370A (ja) * 1993-07-19 1995-02-28 Eli Lilly & Co ワートマンニンおよびその類縁体によるホスファチジルイノシトール3−キナーゼの阻害
US20030139605A1 (en) * 1999-01-13 2003-07-24 Bernd Riedl Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors
WO2003086279A2 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516553A (ja) * 2008-04-09 2011-05-26 ダウ グローバル テクノロジーズ リミティド ライアビリティ カンパニー ジクロロヒドリン類を回収する多段法及び装置
JP2012523429A (ja) * 2009-04-09 2012-10-04 オンコシレオン,インコーポレイテッド 線維症を処置するための方法およびpi−3キナーゼインヒビターの組成物

Also Published As

Publication number Publication date
US20090306020A1 (en) 2009-12-10
AU2006251428A1 (en) 2006-11-30
WO2006125539A2 (en) 2006-11-30
KR20080012902A (ko) 2008-02-12
MX2007014920A (es) 2008-04-09
WO2006125539A3 (en) 2007-03-08
EP1888065A2 (en) 2008-02-20
CA2609387A1 (en) 2006-11-30
IL187085A0 (en) 2008-08-07
BRPI0610090A2 (pt) 2008-12-09

Similar Documents

Publication Publication Date Title
US20090306020A1 (en) Combination therapy comprising diaryl ureas for treating diseases
JP2008542214A (ja) 疾患を処置するためのジアリールウレア化合物およびpi3、aktキナーゼまたはmtor阻害剤(ラパマイシン)を含む組合せ治療
US20090192127A1 (en) Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
KR20100101054A (ko) 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP7109919B2 (ja) Usp7阻害剤化合物及び使用方法
EP3233847A1 (en) Amido thiadiazole derivatives as nadph oxidase inhibitors
JP6381523B2 (ja) Pi−3キナーゼ阻害剤の投与レジメン
AU2011313853A1 (en) Substituted benzamides and their uses
NO342001B1 (no) C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.
CN109843879B (zh) 作为dyrk1抑制剂的苯并噻唑衍生物
AU2019326768B2 (en) 2,6-bis(((1H-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2,N6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer
JP7046250B2 (ja) がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ
WO2020010242A1 (en) Pharmaceutical agents for use in smoking and tobacco cessation
JP4365586B2 (ja) 血管形成阻害活性を有するフタラジン誘導体
CN101180055A (zh) 用于治疗疾病的包含二芳基脲的组合治疗
JP5405760B2 (ja) Plk−1阻害剤
JP2022506289A (ja) インダゾールキナーゼ阻害剤及びその使用
JP2005145928A (ja) 3−キノリン−2(1h)−イリデンインドリン−2−オン誘導体を有効成分とする医薬組成物
HK40057263A (en) 2,6-bis(((1h-benzo[d]imidazol-2-yl)thio)methyl)pyridine and n2,n6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (pi3k) inhibitors for treating cancer
HK1248684B (en) Usp7 inhibitor compounds and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090318

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120814